- Exelixis announced detailed results from the **STELLAR-303** phase 3 pivotal trial, demonstrating that zanzalintinib in combination with atezolizumab improved median overall survival to **10.9 months** compared to **9.4 months** with regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer, significantly reducing the risk of death by **20%**.  **[1042418_9e9e561f414f4c38b6b2f09a6446b2bd_0]** 
- The overall survival benefit was consistently observed across pre-specified subgroups, including geographic region, *RAS* status, liver involvement, and prior anti-VEGF therapy.  **[1042418_9e9e561f414f4c38b6b2f09a6446b2bd_1]** 
- The safety profiles of the combination were generally consistent with previous observations, with Grade 3/4 treatment-related adverse events occurring in **59%** of patients receiving zanzalintinib in combination with atezolizumab and **37%** of patients receiving regorafenib.  **[1042418_9e9e561f414f4c38b6b2f09a6446b2bd_2]** 
- Exelixis plans to complete its first new drug application submission for zanzalintinib in the U.S. in **2025**.  **[1042418_9e9e561f414f4c38b6b2f09a6446b2bd_0]** **[1042418_9e9e561f414f4c38b6b2f09a6446b2bd_1]**

Inhibitor Therapeutics (INTI)